Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Teva Pharmaceutical Industries Ltd. and Active Biotech announced completion of patient enrollment for the second pivotal Phase III clinical trial, BRAVO, evaluating the novel, oral once-daily immunomodulating compound, laquinimod, for the treatment of relapsing-remitting multiple sclerosis. BRAVO is a global clinical trial designed to evaluate the efficacy, safety and tolerability of laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex.

Today in Neuro/Psych pharmacology...keeping you current

An Updated Focused Review of Dexmedetomidine in Adults
Annals of Pharmacotherapy, 12/03/09

Psychotropic Medication Changes, Polypharmacy, and the Risk of Early Readmission in Suicidal Adolescent Inpatients
Annals of Pharmacotherapy, 12/03/09

Safety and Tolerability of Donepezil in Mild Cognitive Impairment: Open-Label Extension Study
American Journal of Alzheimer's Disease and Other Dementias, 12/02/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address